Skip to main content

SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells



Acute myeloid leukaemia (AML) stem cells (LSCs) cause disease relapse. The CD47 “don’t eat me signal” is upregulated on LSCs and contributes to immune evasion by inhibiting phagocytosis through interacting with myeloid-specific signal regulatory protein alpha (SIRPα). Activation of macrophages by blocking CD47 has been successful, but the ubiquitous expression of CD47 on healthy cells poses potential limitations for such therapies. In contrast, CD123 is a well-known LSC-specific surface marker utilized as a therapeutic target. Here, we report the development of SIRPα-αCD123 fusion antibodies that localize the disruption of CD47/SIRPα signalling to AML while specifically enhancing LSC clearance.


SIRPα-αCD123 antibodies were generated by fusing the extracellular domain of SIRPα to an αCD123 antibody. The binding properties of the antibodies were analysed by flow cytometry and surface plasmon resonance. The functional characteristics of the fusion antibodies were determined by antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity assays using primary AML patient cells. Finally, an in vivo engraftment assay was utilized to assess LSC targeting.


SIRPα-αCD123 fusion antibodies exhibited increased binding and preferential targeting of CD123+ CD47+ AML cells even in the presence of CD47+ healthy cells. Furthermore, SIRPα-αCD123 fusion antibodies confined disruption of the CD47-SIRPα axis locally to AML cells. In vitro experiments demonstrated that SIRPα-αCD123 antibodies greatly enhanced AML cell phagocytosis mediated by allogeneic and autologous macrophages. Moreover, SIRPα-αCD123 fusion antibodies efficiently targeted LSCs with in vivo engraftment potential.


SIRPα-αCD123 antibodies combine local CD47 blockade with specific LSC targeting in a single molecule, minimize the risk of targeting healthy cells and efficiently eliminate AML LSCs. These results validate SIRPα-αCD123 antibodies as promising therapeutic interventions for AML.


Therapeutic options for acute myeloid leukaemia (AML) are limited, and the majority of patients relapse due to persistent chemorefractory LSCs [1,2,3]. Targeting and eradicating the leukemic stem cell (LSC) population is therefore a prerequisite for sustained remission. CD47 is an innate immune checkpoint upregulated on LSCs, where it functions as a “don't eat me” signal by interacting with SIRPα on myeloid cells [4,5,6]. The first in class CD47-blocking antibody, magrolimab (Hu5F9-G4), was evaluated as a monotherapy in AML in a phase 1 trial (NCT02678338) [7, 8]. However, preclinical data support the combination of magrolimab with pro-phagocytic signals, such as activation of Fcγ receptors (FcγR) on macrophages or expression of calreticulin on target cells [8,9,10,11,12]. Magrolimab has consequently been combined with calreticulin-inducing azacytidine in a phase 1b trial including untreated AML patients unfit for chemotherapy and patients with intermediate to very high-risk myelodysplastic syndrome (MDS) [8, 13]. The combination demonstrated encouraging results; 64% of AML patients achieved an objective response (OR), while 56% achieved complete remission (CR) or CR with incomplete haematological recovery. In patients with high-risk MDS, 91% had an OR, and 42% had a CR (NCT03248479).

Nevertheless, CD47 is ubiquitously expressed on healthy cells as well, which generates an antigen sink lowering the effective dose and comprising a potential site of toxicity for αCD47 therapies [14, 15]. Combining the CD47 blocking domain, such as endogenous SIRPα, with a cancer-specific antibody in a single molecule can restrict the blockade of CD47 locally on antigen-expressing cells [16,17,18].

Similar to CD47, the interleukin-3 receptor alpha chain (CD123) is upregulated on AML LSCs and is associated with increased proliferation of AML cells and a poor prognosis [19,20,21]. Furthermore, high CD47 and CD123 coexpression has been demonstrated to correlate with AML chemoresistance [22]. These studies suggest that dual targeting of CD123 and CD47 could reduce the LSC count and enhance the rate and duration of response in AML patients.

To improve AML LSC targeting and clearance, we fused an αCD123 antibody with the endogenous N-terminal SIRPα immunoglobulin V-like domains and generated 1 × SIRPα-αCD123 and 2 × SIRPα-αCD123 fusion antibodies. Both of our antibodies exhibited improved binding to CD123+ CD47+ cells and stimulated efficient natural killer (NK) cell-mediated lysis of AML compared to the conventional αCD123 antibody in vitro. Importantly, SIRPα-αCD123 fusion antibodies blocked CD47 locally on CD123+ cells and induced phagocytosis of primary AML cells by allogeneic and autologous macrophages in vitro. Finally, the 2 × SIRPα-αCD123 antibody targeted LSCs that are capable of engrafting and reinitiating AML in an in vivo model.

Materials and methods

Expression and purification of the antibodies

αCD123 antibody light and heavy chain plasmids were generated by cloning the αCD123 variable light (VL) and variable heavy (VH) sequences of talacotuzumab [23] into the respective pFUSE2-CLIg-hK and pFUSE-CHIg-hG1 vectors (InvivoGen). For 1 × SIRPα-αCD123 and 2 × SIRPα-αCD123, one or two N-terminal SIRPα variant 1 immunoglobulin V-like domains (amino acids 31-149) were subcloned from a previously described construct [18] into the N-terminus of the αCD123 VL using a (Gly4Ser)4 linker. The αCD19 VL and VH plasmids (clone 4G7) were cloned to generate the control molecules. The αCD47 (clone Hu5F9) VL and VH sequences [24] were subcloned into pFUSE2-CLIg-hK and pFUSE-CHIg-hG4, respectively. The SIRPα-Fc fusion construct (similar to TTI-621) [25] was generated by fusing the N-terminal V domain of human SIRPα variant 2 [26] to the human IgG1 Fc region of a pFUSE-CHIg-hG1 vector (InvivoGen). The plasmids were transfected into Expi293F cells (Thermo Fisher Scientific) according to the manufacturer’s protocol. After five to seven days, the supernatant was harvested, and antibodies were purified by protein A affinity chromatography followed by size exclusion chromatography using a Superdex 200 increase 10/300 GL column (GE Healthcare). Antibodies were analysed by sodium dodecyl sulphate (SDS) polyacrylamide gel electrophoresis, and stability was measured using a Tycho NT.6 (NanoTemper Technologies). The coding sequence for the CD123 extracellular domain was amplified by PCR from complementary DNA of L-428 cells and subcloned into pSecTag2/HygroC containing a His6-tag (Thermo Fisher Scientific). CD123 was expressed in Expi293F cells and purified by nickel affinity chromatography and size exclusion chromatography.

Surface plasmon resonance analysis

Binding of the αCD123 antibodies to CD123 was measured using a Biacore X100 (Biacore). Antibodies were captured on a CM5 sensor chip using the Human Antibody Capture Kit (both GE Healthcare). CD123 was used at concentrations of 3.91–1000 nM, and equilibrium dissociation constants (KD) were calculated from the ratio of the rate constants (koff/kon) of the multicycle kinetics measurements using Biacore Evaluation software.

Cell lines

All cell lines were cultured under standard conditions. MOLM-13 and Raji cells were purchased from the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ). Chinese hamster ovary (CHO) cells stably overexpressing human CD47 were previously generated [18]. Expi293F cells were obtained from Thermo Fisher Scientific. Cell lines were routinely screened for mycoplasma contamination.

Patient and healthy donor material

At initial diagnosis or relapse, AML patient samples were characterized at the Laboratory for Leukemia Diagnostics of the Klinikum der Universität München as previously described [27,28,29]. Peripheral blood mononuclear cells (PBMCs) were isolated from healthy donor (HD) blood or residual cells of leukoreduction chambers by Biocoll (Biochrom). RBCs were collected from HD peripheral blood. Platelet-rich plasma (PRP) was isolated from HD peripheral blood by centrifugation at 200×g for 20 min at 25 °C. In the binding studies, platelets were isolated from PRP in the presence of prostaglandin E1 (Merck). For patient-derived xenograft (PDX) cells, AML patient cells were serially transplanted into NOD/SCID gamma null mice (NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ, NSG). PDX cells were transduced with luciferase and mCherry lentiviral constructs for bioluminescence imaging [23]. For ex vivo experiments, PDX cells were grown in StemPro-34 medium with 2% FBS, L-glutamine and penicillin–streptomycin (all Gibco) supplemented with rhIL3, rhTPO, rhSCF (all Peprotech) and rhFLT3-ligand (R&D Systems). Patient characteristics are summarized in Table 1 and Additional file 1: Table S1.

Table 1 Patient characteristics

Antibodies and flow cytometry

Commercial antibodies were from Biolegend (San Diego) unless otherwise stated. Human IgG1 isotype control (QA16A12) and αCD47 (B6H12, eBioscience) were used in binding, CD47 blocking and functional experiments. FITC or APC α human IgG (αhIgG, HP6017) was used for binding, and FITC αCD47 (B6H12, eBioscience) was used in CD47 blocking experiments for secondary staining. APC and FITC isotype (MOPC-21), APC αCD123 (6H6) and FITC αCD47 (B6H12) were used for surface expression analysis. Surface antigen density was evaluated using QIFIKIT (Agilent Technologies). Flow cytometry was performed using the Guava easyCyte 6HT (Merck Millipore), the Cytoflex LX (Beckman Coulter) or the BD LSRFortessa (Becton Dickinson). As a measure of antibody binding, the median fluorescence intensity (MFI) ratio was calculated by dividing the MFI of the tested antibody by the MFI of the corresponding isotype. Antibodies were considered to bind the cells if the intensity exceeded an MFI ratio of 1.5.

Competitive binding assays

PKH26 (Sigma-Aldrich)-labelled MOLM-13 was incubated with a 20-fold excess of red blood cells (RBCs) and antibodies. APC αhIgG (HP6017) or APC αmIgG (Poly4053) was used for secondary labelling. For assays with PBMCs, calcein AM (Thermo Fisher Scientific) or CellTrace™ calcein red-orange AM (Thermo Fisher Scientific)-labelled MOLM-13 cells were incubated with a fivefold excess of PBMCs and antibodies. APC or FITC αhIgG (HP6017) was used for secondary antibody labelling.

Platelet aggregation

PRP was centrifuged at 15,000×g for 2 min to obtain platelet-poor plasma (PPP). PRP was incubated in the presence of 100 nM antibodies, and absorbance was measured at 595 nm using an Infinite M100 plate reader (TECAN) for 16 min. The percentage of aggregation was calculated as \(({\text{platelet aggregation}} \left[ \% \right] = 100 \times \frac{{\left( {\text{OD PRP - OD sample}} \right)}}{{\left( {\text{OD PRP - OD PPP}} \right)}})\) [30].

Antibody-dependent cellular phagocytosis (ADCP) assay

Monocytes were enriched using a classical monocyte isolation kit (Miltenyi) and were differentiated into macrophages in the presence of 100 ng/ml MCSF (Biolegend) for 5–7 days. Macrophages were labelled with calcein AM and incubated with CellTrace™ calcein red-orange AM-labelled target cells and antibodies at 50 pM or 50 nM for 3 h at 37 °C at a 1:1 effector-to-target (E:T) ratio.

Antibody-dependent cellular cytotoxicity (ADCC) assays

NK cells were enriched using a NK cell isolation kit (Miltenyi). MOLM-13 cells were labelled with calcein AM and incubated with NK cells and antibodies for 4 h at 37 °C at a 5:1 E:T ratio. In the competitive ADCC assay, NK cells were incubated with labelled MOLM-13 or Raji cells mixed with unlabelled Raji or MOLM-13 cells, respectively, at a 5:1:1 E:T:T ratio. Triton X-100 (2.5%, Sigma-Aldrich) was used for maximum lysis. Fluorescence intensity (FI) from calcein AM release was measured using an Infinite M100 plate reader, and lysis was calculated as (\({\text{specific lysis}} \left[ \% \right] = 100 \times \frac{{{\text{FI}}\left( {\text{antibody stimulation}} \right) - {\text{FI}}\left( {{\text{untreated}}} \right)}}{{{\text{FI}}(\max ) - {\text{FI}}\left( {{\text{target}}} \right)}}\)). Data were fitted to a four-parameter dose–response curve.

ADCC assays of AML patient samples were performed in α-MEM (Thermo Fisher Scientific) supplemented with 12.5% foetal calf serum, 12.5% horse serum, 1% penicillin, 1% streptomycin, 1% glutamine (Invitrogen) and a distinct cytokine cocktail on irradiated MS-5 cells in a long-term culture as described elsewhere [31, 32]. AML cells were incubated with HD NK cells and 10 nM antibodies for 20 h at 37 °C at a 5:1 E:T ratio. Dead cells were excluded as 7-AAD (BioLegend) or LIVE/DEAD™ Fixable Aqua (Thermo Fisher Scientific)-positive cells. CD33+ or CD123+ AML cells were determined by BV421, APC αhCD33 (WM53) or PE αhCD123 (6H6) labelling, respectively. Additionally, APC-Cy7 or FITC αhCD69 (FN50) and the corresponding isotype control (MOPC-21) were used to determine the percentage of CD69+ cells. In some experiments, NK cells were labelled with CellTrace™ CFSE or CellTrace™ Far Red (both Thermo Fisher Scientific) according to the manufacturer’s recommendations. Cell populations were assessed by flow cytometry, and the percentage of viable CD33+ or CD123+ AML cells was normalized to the human IgG1 isotype control sample. The percentage of CD69+ cells was normalized to the human IgG1 isotype control sample.

In the AML PDX ADCC, AML-491, AML-979, and AML-640 were incubated with NK cells and 100 nM antibodies for 20 h at 37 °C at a 5:1 E:T ratio. Cells were labelled with LIVE/DEAD Fixable Aqua, and the proportion of live mCherry+ cells was determined by flow cytometry and normalized to the isotype control.

In vivo engraftment experiments

To evaluate the targeting of AML cells with leukaemia-initiating properties, ex vivo NK cell-mediated ADCC was performed using the αCD123 antibody, the 2 × SIRPα-αCD123 fusion antibody or isotype antibody as a control, and surviving cells were used in an in vivo engraftment experiment. To this end, PDXs AML-491 and AML-579 [33, 34] were incubated with HD NK cells at an E:T ratio of 5:1 and antibodies for 20 h. After ADCC, residual mCherry+ PDX cells were separated from NK cells and quantified by fluorescence-activated cell sorting (FACS) using a FACSAria III (BD Biosciences). According to previous data [34] and assuming that the isotype control antibody did not alter LIC frequency, we injected cell numbers corresponding to 10 leukaemia-initiating cells (10 × LIC, n = 5) and 100 × LIC (n = 5) for AML-491 or 14 × LIC (n = 4) and 140 × LIC (n = 2) for AML-579 by counting and diluting sorted cells of the isotype control suspensions. To enable comparison between the groups, equal volumes of αCD123 and 2 × SIRPα-αCD123 antibody ex vivo cell suspensions were sorted and injected intravenously into 10- to 12-week-old male (AML-491) or female (AML-579) NSG mice. Positive AML engraftment was analysed by in vivo bioluminescence imaging (BLI), and total flux was quantified as previously described [33]. Mice exhibiting a total flux greater than 5 × 107 photons per second were classified as exhibiting positive engraftment; mice displaying no positive imaging signal within 28 weeks after transplantation were classified as negative for engraftment. To evaluate the percentage of human CD33+ cells in peripheral blood, PE anti-human CD33 (WM53, BD Biosciences) and PE isotype control (MOPC-21, BD Biosciences) were used. Mice exhibiting any clinical signs of illness or end-stage leukaemia (total flux > 2 × 1010 photons/s; hCD33+ cells in peripheral blood > 50%) were euthanized. Three mice died in narcosis during imaging and were counted as positive according to the last imaging signal or were excluded if not engrafted.

Data analysis

Statistical evaluation was performed using GraphPad Prism versions 6.07 and 8.1.2 (GraphPad). Datasets were analysed using one-way analysis of variance (ANOVA) including a test to determine equal variances within the groups and correction for multiple testing using Holm-Sidak's test. Chi-squared test was used to determine whether there is a statistically significant difference in the growth of engrafted AML PDX cells. A Kaplan–Meier plot was generated to depict AML engraftment and survival by treatment group, and significance was assessed using the log-rank Mantel-Cox test. Extreme limiting dilution analysis was performed using the injected cell number and number of AML engrafted mice as inputs as previously described [35] (Figure 7; Additional file 1: Table S2). The results were considered statistically significant at the following values and are marked in the figures as follows: p value < 0.05 (*), < 0.01 (**), < 0.001 (***), < 0.0001 (****).


Generation and characterization of SIRPα-αCD123 fusion antibodies

The 1 × SIRPα-αCD123 recombinant antibody was generated by fusing the N-terminal SIRPα immunoglobulin V-like domain to the αCD123 antibody light chain via a flexible polypeptide linker (Fig. 1A). Likewise, for 2 × SIRPα-αCD123, a second SIRPα domain was connected to the N-terminus of 1 × SIRPα-αCD123 (Fig. 1A). Antibodies were produced in Expi293F cells, purified from cell culture supernatants and analysed by size exclusion chromatography and SDS–polyacrylamide gel electrophoresis (Additional file 1: Figure S1A-B). Thermal stability was assessed by measuring changes in the intrinsic fluorescence of the proteins using Tycho NT.6 (Additional file 1: Figure S1C). To investigate whether the N-terminal fusion of the SIRPα domains alters the binding to CD123, we determined the KD values using a Biacore assay. The KD values were in the low nanomolar range for all constructs, indicating that the high affinity for CD123 was not affected by the fusion of the SIRPα domains (Fig. 1B). We further evaluated binding of the antibodies to CHO cells stably overexpressing human CD47 (hCD47) by flow cytometry (Table 2). As expected, 1 × SIRPα-αCD123 and 2 × SIRPα-αCD123 bound to+CHO_hCD47+ cells but not to CHO_hCD47- cells (Fig. 1C). These binding experiments indicate that the αCD123 and SIRPα domains can bind to their respective targets in the fusion antibody.

Fig. 1

SIRPα-αCD123 fusion antibodies bind to CD123 and CD47. A Structure of SIRPα-αCD123 fusion antibodies. VH—variable heavy, CL—constant light, CH1—constant heavy 1, CH2—constant heavy 2, CH3—constant heavy 3. B Different CD123 concentrations binding to the antibody constructs measured using SPR. Raw data are shown in red; black curves were fitted to a 1:1 interaction. KD values represent mean values from n = 3 independent experiments ± standard error of the mean (SEM). C Binding of antibodies to CHO_hCD47+ and CHO_hCD47 cells at 100 nM concentration measured by flow cytometry. The grey line indicates nonspecific staining of the isotype control and secondary antibody. Histograms show 1 of 3 experiments with similar results

Table 2 Antigen expression levels

SIRPα-αCD123 fusion antibodies specifically bind to CD123+CD47+ AML cells

Next, we used the CD123+ CD47+ AML cell line MOLM-13 in a flow cytometry-based binding assay to study the dual targeting properties of the antibody constructs (Fig. 2A, Table 2). The binding of 1 × SIRPα-αCD123 and 2 × SIRPα-αCD123 to MOLM-13 cells was stronger than that of the αCD123 antibody, indicating a contribution by the SIRPα domain. The αCD19 SIRPα fusion antibodies mediated only weak binding to CD19 MOLM-13 cells due to some low binding of the SIRPα domains (Fig. 2A, Table 2). In summary, we hypothesize that the strong binding of the SIRPα-αCD123 antibodies to MOLM-13 cells is due to avidity-dependent binding to both CD123 and CD47.

Fig. 2

SIRPα-αCD123 fusion antibodies preferentially bind to MOLM-13 cells in the presence of RBCs. A Binding of SIRPα-αCD123 fusion antibodies to MOLM-13 cells assessed by flow cytometry-based MFI ratio. The dotted line indicates an MFI ratio of 1.5 as the cut-off for positivity. Shown are the mean values from n = 2–3 independent experiments ± SEM. B Percentage of 100 nM antibodies targeting MOLM-13 cells or RBCs measured by flow cytometry at a 20-fold excess of RBCs. C MFI ratios of antibody binding to MOLM-13 cells in the presence of a 20-fold excess of RBCs. D MFI ratios of antibody binding to RBCs in the presence of MOLM-13 cells. The results of independent experiments with 4 different RBC donors represented as the mean ± SEM are shown. E Percentage of 100 nM antibodies targeting MOLM-13 cells or PBMCs measured by flow cytometry at a fivefold excess of PBMCs. Shown are mean values from n = 6 donors ± SEM. F Binding of SIRPα-αCD123 fusion antibodies to PBMCs assessed by flow cytometry-based MFI ratio. Shown are mean values from n = 5 donors ± SEM. G Binding of SIRPα-αCD123 fusion antibodies to platelets assessed by flow cytometry-based MFI ratio. Mean values from n = 4 donors ± SEM are shown. H Platelet aggregation induced by 100 nM antibody over time. Mean values from n = 4 donors ± SEM are shown. F and H p values are the same for both SIRPα-αCD123 fusion antibodies. Statistical differences were determined by one-way ANOVA using Holm–Sidak's post hoc test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

The physiological interaction of the SIRPα domain and CD47 is approximately 100-fold weaker than the affinity of the αCD123 antibody for CD123 [26, 36]. Therefore, we postulated that the high affinity αCD123 drives the preferential binding of SIRPα-αCD123 fusion antibodies onto CD123+CD47+ leukemic cells over CD123¯CD47+ healthy cells. To test this hypothesis, we first utilized RBCs as highly abundant healthy cells expressing CD47 (Fig. 2B, Table 2).

We observed selective binding to MOLM-13 cells using the 1 × SIRPα-αCD123 antibody even in the presence of a 20-fold excess of RBCs (Fig. 2B, C). 2 × SIRPα-αCD123, on the other hand, was also detected on the surface of RBCs, indicating that the additional SIRPα domains can increase the competition between CD47+ MOLM-13 cells and RBCs (Fig. 2B, C). Nevertheless, the RBC targeting observed for 2 × SIRPα-αCD123 was very weak, with a binding intensity far below an MFI ratio of 1.5 (Fig. 2D). In contrast, the high affinity αCD47 B6H12 antibody demonstrated a substantial on-target off-leukaemia effect, as it primarily bound to RBCs with a high MFI ratio (Fig. 2B–D). We concluded that despite carrying the SIRPα domains, the SIRPα-αCD123 fusion antibodies target MOLM-13 cells more than the high affinity αCD47 and avoid the antigen sink generated by the RBCs.

In another set of experiments, we investigated the selective binding of our antibodies to MOLM-13 cells in the presence of HD PBMCs (Fig. 2E). From PBMCs, plasmacytoid dendritic cells express CD123 and are targeted by the αCD123 antibody CSL362 [37]. We also found that some of our αCD123 binds to PBMCs; however, the majority of the antibodies still bound to MOLM-13 cells (Fig. 2E). The 1 × SIRPα-αCD123 antibody bound PBMCs to a considerable extent, but higher selective binding to MOLM-13 cells was observed compared to the αCD47 Hu5F9-G4 clone. 2 × SIRPα-αCD123 targeted MOLM-13 cells similarly to αCD47 Hu5F9-G4. However, when we analysed binding of the antibodies to PBMCs alone, we observed that our fusion antibodies bound PBMCs significantly less than the αCD47 Hu5F9-G4 and B6H12 antibodies (Fig. 2F). These data indicate that although our fusion antibodies seem to target PBMCs more than RBCs, they bind to PBMCs to a lesser extent than the high affinity αCD47 antibodies.

In addition to binding to RBCs, CD47-targeting agents have been reported to bind platelets and interfere with their function [38, 39]. We therefore investigated whether our SIRPα-αCD123 fusion antibodies target platelets and induce their aggregation (Fig. 2G–H). Indeed, SIRPα-αCD123 fusion antibodies bound to platelets similarly to the SIRPα-Fc construct but less than the αCD47 Hu5F9-G4 control (Fig. 2G). However, SIRPα-αCD123 antibodies did not induce aggregation of platelets, unlike SIRPα-Fc, αCD47 Hu5F9-G4 and especially αCD47 B6H12 antibodies (Fig. 2H). These experiments suggest that binding of the constructs does not directly correlate with a functional effect and indicate that our SIRPα-αCD123 fusion antibodies do not stimulate platelet aggregation.

SIRPα-αCD123 fusion antibodies block CD47 and induce phagocytosis of MOLM-13 cells in vitro

SIRPα-αCD123 fusion antibodies were designed to inhibit the CD47-SIRPα axis locally on CD123+ cells. To examine this, we performed a blocking assay using labelled αCD47 antibodies that interfere with the binding of SIRPα. Despite the weak affinities of the SIRPα domains, 1 × SIRPα-αCD123 and 2 × SIRPα-αCD123 were able to block CD47 molecules on MOLM-13 cells. Not surprisingly, maximum blockade was observed with the high affinity αCD47 antibody. In comparison, 1 × SIRPα-αCD123 did not block CD47 on CD123¯ Raji cells, and 2 × SIRPα-αCD123 minimally blocked CD47 (Additional file 1: Figure S2A), indicating that binding of the αCD123 moiety to target cells is required for efficient disruption of the CD47-SIRPα axis.

We next examined whether CD47 blockade with concomitant engagement of FcγRs stimulates the ADCP of MOLM-13 cells by HD-derived macrophages (Fig. 3B). Indeed, phagocytosis was significantly boosted by 1 × SIRPα-αCD123 compared to αCD123. 2 × SIRPα-αCD123 also induced elevated phagocytosis, but this was not statistically significant. In contrast, αCD47 did not stimulate phagocytosis either alone or in combination with αCD123 in this setting. The respective αCD19 controls did not have an effect on phagocytosis. In summary, SIRPα-αCD123 fusion antibodies boost ADCP in MOLM-13 cells, whereas αCD123 and αCD47 antibodies alone lack this ability.

Fig. 3

SIRPα-αCD123 fusion antibodies block CD47 and stimulate phagocytosis of MOLM-13. A CD47 blockade on MOLM-13 cells with 100 nM antibodies determined by FITC αCD47 binding using flow cytometry. Background fluorescence was subtracted from the FITC αCD47 signal and normalized to isotype to calculate the CD47 blockade. Mean ± SEM of n = 4 independent experiments. B ADCP of MOLM-13 cells at a 50 pM concentration of antibodies after 3 h at an E:T ratio of 1:1. ADCP was measured as the percentage of double-positive cells from macrophages and normalized to the isotype control. Bar charts represent the mean ± SEM from n = 7 different donors. Statistical differences were determined by one-way ANOVA using Holm-Sidak's post hoc test. *p < 0.05, ***p < 0.001, ****p < 0.0001, not significant (ns)

SIRPα-αCD123 fusion antibodies induce enhanced phagocytosis of patient-derived AML cells by allogeneic and autologous macrophages in vitro

We further investigated the stimulation of phagocytosis by SIRPα-αCD123 antibodies using primary AML patient-derived blasts as targets and allogeneic or autologous monocyte-derived macrophages as effector cells (Fig. 4A, B). We observed enhanced overall phagocytosis by primary AML cells compared to MOLM-13 cells. Allogeneic macrophages from HDs mediated significantly higher ADCP with the 1 × SIRPα-αCD123 fusion antibody compared to αCD123. The 2 × SIRPα-αCD123 had a similar effect (Fig. 4A). More importantly, these results were confirmed in the autologous setting (Fig. 4B). Phagocytosis mediated by 1 × SIRPα-αCD123 and 2 × SIRPα-CD123 was significantly higher than that mediated by αCD123. αCD47 antibodies B6H12 and Hu5F9-G4 alone or in combination with αCD123 antibody induced similar ADCP as SIRPα-αCD123 fusion antibodies. When comparing SIRPα-CD123 fusion antibodies to similar αCD33-based constructs [18], we did not observe significant differences in the ability to induce phagocytosis of AML cells (Fig. 4B). Taken together, these data reveal that SIRPα-αCD123 fusion antibodies represent an effective tool to overcome the CD47-mediated inhibition of phagocytosis in AML.

Fig. 4

SIRPα-αCD123 fusion antibodies stimulate phagocytosis of AML patient cells by allogeneic and autologous macrophages. AML target cells and macrophages were incubated with 50 nM antibody for 3 h at an E:T ratio of 1:1. ADCP was measured as the percentage of double-positive cells (gated) from all macrophages. Each symbol represents one patient (Table 1). A Phagocytosis of AML patient cells by allogeneic macrophages (n = 4). B Phagocytosis of AML patient cells by autologous macrophages (n = 10). Statistical differences were determined by one-way ANOVA using Holm-Sidak's post hoc test. *p < 0.05, ****p < 0.0001, not significant (ns)

SIRPα-αCD123 fusion antibodies induce NK cell-mediated specific lysis of AML cells in vitro

ADCC by NK cells is one of the primary mechanisms by which IgG1 antibodies induce the elimination of antibody-bound cells in addition to macrophage-mediated ADCP [40]. Therefore, we analysed specific lysis of MOLM-13 cells by HD-derived NK cells (Fig. 5A). αCD123 induced moderate dose-dependent lysis of MOLM-13, whereas 1 × SIRPα-αCD123 and 2 × SIRPα-αCD123 were more potent. We postulated that SIRPα-αCD123 fusion antibodies are more efficient due to the avidity-dependent targeting of both CD123 and CD47. The respective αCD19 controls induced lysis of MOLM-13 cells only at high concentrations, which can be attributed to autonomous targeting of CD47 by the fused SIRPα domain. Nevertheless, the half maximal effective concentration (EC50) was considerably lower for 2 × SIRPα-αCD123 (19.1 pM) than for the 2 × SIRPα αCD19 analogue (192.1 pM), demonstrating target antigen-specific cytotoxicity. This was further demonstrated in a competitive ADCC assay in which CD123+ MOLM-13 cells were mixed with CD123¯ Raji cells (Additional file 1: Figure S2B). In this setting, Raji cells were not lysed by 1 × SIRPα-αCD123 and 2 × SIRPα-αCD123 only exerted an effect at high concentrations. In summary, although independent binding of the SIRPα domains can cause some lysis of target cells at high concentrations, we consider high affinity αCD123 binding to be a prerequisite for targeting by SIRPα-αCD123 fusion antibodies.

Fig. 5

SIRPα-αCD123 fusion antibodies enhance NK cell-mediated lysis of MOLM-13 and PDX AML cells. A NK cell-mediated dose-dependent lysis of MOLM-13 cells after 4 h at an E:T ratio of 5:1 measured by calcein AM release. Mean values ± SEM for n = 6 different NK cell donors are shown. EC50 values were calculated where possible. B Expression of CD123, CD33 and CD47 in primary AML samples assessed by flow cytometry. C, D NK cell-mediated lysis of AML cells in long-term culture at a 10 nM antibody concentration after 20 h at an E:T ratio of 5:1 measured by flow cytometry. The results from n = 7 different AML patient samples are represented as different symbols, and their mean values are shown. E Percentage of CD69+ cells measured by flow cytometry. F NK cell-mediated lysis of PDX cells at 100 nM antibody concentration after 20 h at an E:T ratio of 5:1 measured by flow cytometry. The results from n = 3 different AML patient samples are represented as different symbols, and their mean values are shown. Statistical differences were determined by one-way ANOVA using Holm-Sidak's post hoc test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001

The ability of SIRPα-αCD123 fusion antibodies to activate NK cells was further investigated using AML patient cells. First, we used blasts from primary AML patients (Fig. 5B) in a long-term culture system with HD-derived NK cells as effectors [31]. Compared to isotype controls and αCD123, 1 × SIRPα-αCD123 and 2 × SIRPα-αCD123 antibodies significantly boosted the cytotoxicity by NK cells, leading to reduced numbers of AML cells (Fig. 5C). As expected, the αCD47 antibodies B6H12 and Hu5F9-G4 and the 1 × SIRPα αCD19 control molecule did not stimulate lysis of AML cells (Fig. 5C). From the αCD33 constructs, only the 2 × SIRPα αCD33 analogue induced significant lysis of AML cells compared to the isotype control (Fig. 5D). When analysing the NK cell population of the ADCC samples, we observed a significant upregulation of the activation marker CD69 with 1 ×- and 2 × SIRPα-αCD123 (Fig. 5E). Treatment with 2 × SIRPα-αCD123 induced especially potent CD69 upregulation, which was also significantly greater than that induced by the 2 × SIRPα αCD33 analogue (Fig. 5E). Interestingly, the αCD47 antibody Hu5F9-G4 induced slight upregulation of CD69 (Fig. 5E). Together, these results demonstrate that in addition to highly effective FcγR-dependent ADCC stimulation, SIRPα-αCD123 antibodies might further activate NK cells via mechanisms related to CD47 blockade.

Next, we used AML PDX cells as target cells. Here, we observed that 1 × SIRPα-αCD123 and 2 × SIRPα-αCD123 both dramatically increased the lysis of AML PDX cells compared to αCD123 (Fig. 5E). This again highlights that our fusion antibodies enhance NK cell-mediated lysis of patient-derived AML cells.

SIRPα-αCD123 fusion antibodies have the potential to target AML stem cells

Specific targeting of AML LSCs is needed to prevent relapse and enhance the rate and duration of response to therapy in patients. We hypothesized that SIRPα-αCD123 fusion antibodies would efficiently eliminate CD123high CD47high LSCs due to the avidity-dependent binding of the αCD123 and SIRPα moieties. Xenograft mouse models have been widely used to investigate leukaemia-initiating cells (LICs) as surrogates for LSCs [41, 42]. To evaluate the impact of HD NK cell-dependent cytotoxicity of our antibodies on LICs, we performed an in vivo engraftment assay using residual AML PDX cells that survived an ex vivo ADCC assay (Fig. 6A). We expect that LICs are killed more efficiently with SIRPα-αCD123 fusion antibodies than with αCD123 antibodies in the ex vivo ADCC assay and thus lead to reduced engraftment of AML cells. To this end, PDX cells from two AML patients were incubated with NK cells and isotype control, αCD123 or 2 × SIRPα-αCD123 (Additional file 1: Figure S3). Only the 2 × SIRPα-αCD123 fusion antibody was used as it showed superior killing of AML PDX cells (Fig. 5F). After this ADCC, surviving PDX cells were sorted and injected into NSG mice at two doses corresponding to 10 leukaemia-initiating cells (10 × LIC) or 100 × LIC. AML engraftment was analysed by in vivo BLI and peripheral blood analysis.

Fig. 6

Ex vivo treatment with 2 × SIRPα-αCD123 prevents outgrowth of AML-491 PDX cells in vivo. A Experimental design of the engraftment assay. Residual AML cell from ADCC in (Additional file 1: Figure 3A, B) was FACS sorted, and equal volumes were injected intravenously into NSG mice. Mice were monitored using in vivo BLI. B, C AML burden in individual mice of the 10 × LIC and 100 × LIC groups measured by BLI. The dotted line indicates a total flux of 5 × 107 photons/s as the cut-off for evaluating positive AML engraftment. Statistical analysis was performed using Chi-squared test. Representative images of mice injected with 10 × LIC (D) and 100 × LIC (E) on day (d) 62. Mice that died in narcosis during imaging (d.i.n.) were counted as positive if the last imaging signal showed positive engraftment (p. e.) or were excluded from analysis (ex.) if not engrafted. F Kaplan–Meier curve of AML-491 engraftment analysed by BLI. (G) Kaplan–Meier curves showing survival of mice. Statistical significance was calculated using the log-rank test. *p < 0.05, **p < 0.01, not significant (ns)

As expected, all mice that received residual cells from isotype control-treated AML-491 ADCC culture exhibited PDX cell engraftment soon after transplantation [10 × LIC: 28–49 days post injection (dpi), n = 5; 100 × LIC: 33 dpi, n = 5], whereas treatment with the αCD123 antibody slightly delayed the time to positive engraftment (10 × LIC: 62–91 dpi, n = 5; AML-491 100 × LIC: 49 dpi, n = 4) (Fig. 6B–F). Importantly, residual cells from 2 × SIRPα-αCD123 ADCC cultures exhibited a dramatically reduced engraftment capacity, with only one animal in the 10 × LIC group (114 dpi) and none in the 100 × LIC group showing positive engraftment (Fig. 6B–F). All mice with positive engraftment reached end-stage leukaemia with high BLI signals and hCD33+ cells in peripheral blood (Fig. 6; Additional file 1: Figure S5). AML-579 cells were injected at slightly higher doses of 14 × LIC and 140 × LIC, but the results were similar to those observed for AML-491 (Additional file 1: Figures S4 and S5).

We used the extreme limiting dilution analysis algorithm to determine whether the nearly absent engraftment in the 2 × SIRPα-αCD123 condition was due to specific LIC targeting or a lower number of injected residual cells [35]. Even though all mice in the isotype and αCD123 treatment groups exhibited engraftment, a significant difference in the estimated LIC frequencies was detected between αCD123 and 2 × SIRPα-αCD123 for AML-491 (Fig. 7A, B; Additional file 1: Table S2). We concluded that while 2 × SIRPα-αCD123 markedly reduces the number of bulk AML cells, it targets leukemic stem cells with an even higher preference.

Fig. 7

LIC frequencies of AML-491 after NK cell-mediated lysis with the 2 × SIRPα-αCD123 fusion antibody. A Engraftment at each injected cell dose for each antibody. Residual AML cells were counted during cell sorting before injection. B LIC frequencies were estimated using extreme limiting dilution analysis software [35]. Horizontal lines indicate the estimated LIC frequencies, and the bars indicate 95% confidence intervals


The ubiquitously expressed surface marker CD47 interacts with the SIRPα receptor to inhibit myeloid cell-mediated phagocytosis of autologous cells [4, 14, 15]. Blocking the CD47-SIRPα checkpoint as an anticancer therapy is under intense investigation since CD47 is overexpressed on AML as well as on various other cancer types [5, 10, 43]. However, ubiquitous expression of CD47 creates an antigen sink that can sequester CD47-targeting agents and reduce the effective dose. Moreover, nonspecific targeting can cause toxicities to healthy cells, as CD47 has various roles in physiological tissue homeostasis [44]. For example, the CD47 ligand SIRPγ is expressed on human T cells, and targeting CD47 with a mAb has been shown to affect human T cell responses [45].

The most serious side effects reported from CD47-targeting agents in clinical trials are anaemia and thrombocytopenia [39, 46,47,48,49]. The SIRPα-αCD123 antibodies presented here specifically bind to the AML cell line MOLM-13 in the presence of excess RBCs, in contrast to the high-affinity CD47-targeting antibody B6H12. These results agree with previous reports where similar constructs targeting CD33 and CD20 avoid the CD47 sink generated by RBCs [17, 18]. We also observed that SIRPα-αCD123 antibodies targeted PBMCs more than RBCs. The low-affinity SIRPα-dependent binding to PBMCs might, however, not lead to activation of macrophages or NK cells based on our results with SIRPα-αCD19 control molecules in experiments with MOLM-13 cells and primary AML cells. Importantly, although the SIRPα-αCD123 fusion antibodies also bind platelets, they do not induce any aggregation, unlike other CD47-targeting molecules tested herein. The underlying reason for this might be a combination of relatively low-affinity binding of the SIRPα domain to CD47 as well as different steric features of the antibody constructs.

Despite the low-affinity binding of the SIRPα domains, SIRPα-αCD123 fusion antibodies were able to induce the same or even higher phagocytosis than high affinity αCD47 either alone or in combination with αCD123. This is in line with the well-known synergy between CD47-SIRPa axis disruption and prophagocytic signals [8, 10, 50,51,52] and supports the rationale of combining CD47 blockade and FcγR stimulation into one molecule.

AML LSCs reside in specific niches in the bone marrow [53]. Antibodies can freely access the bone marrow through sinusoidal clefts and therefore represent a promising therapeutic strategy for targeting LSCs in their microenvironment [54]. CD33-targeting gemtuzumab ozogamicin is currently the only antibody-based therapy approved for AML [55]. Unfortunately, only some patients are likely to benefit from gemtuzumab ozogamicin [56, 57]. CD33/CD47 cotargeting has been previously preclinically investigated [18, 58]. However, bivalent mAbs against CD33 have been shown to internalize upon cross-linking, which can compromise the immune response [59, 60]. Expression of CD33 on LSCs is also associated with variability, which might affect therapeutic outcomes [20, 61]. Our results indicate that the SIRPα-αCD123 constructs are comparable to αCD33-based fusion antibodies in inducing autologous ADCP or allogenic ADCC. Interestingly, we observed much higher activation of NK cells in response to 2 × SIRPα-αCD123 than with the αCD33 analogue. Whether this was due to CD33-related internalization effects or other reasons remains to be investigated, but we consider αCD123-based constructs promising candidates next to αCD33-targeting antibodies.

Because chemorefractory LSCs build a reservoir for relapse, elimination of these cells is essential for AML treatment [1, 2]. In younger adults, a lower percentage of CD123+ LSCs at diagnosis is correlated with a better response to treatment and survival [62]. Similarly, in older patients who are fit for intensive chemotherapy, survival was higher in those who displayed lower levels of CD123+ LSCs [63]. Therefore, eliminating or reducing the numbers of CD123+ LSCs might lead to more durable responses and prolonged survival. We show here that compared to αCD123, SIRPα-αCD123 antibodies exhibit increased targeting efficacy of CD123+ CD47+ AML cells due to avidity-dependent binding to both antigens. Our fusion antibodies could take advantage of the high expression of both CD123 and CD47 on LSCs and effectively address this population. Indeed, we observed an extreme reduction in the engraftment of AML after an ex vivo ADCC assay with the 2 × SIRPα-αCD123 antibody, as our antibodies stimulated NK cell-mediated cytotoxic lysis of AML LSCs. The increased avidity of SIRPα-αCD123 antibodies thus provides the opportunity to preferentially target and eliminate AML LSCs.

Because of avidity-dependent binding to CD123 and CD47, SIRPα-αCD123 antibodies could further target malignant LSCs cells over healthy haematopoietic stem cells, which express low levels of CD47 and minimal amounts of CD123 [5, 19, 21, 64]. The 2 × SIRPα-αCD123 fusion antibody facilitated the most potent NK cell activation in our assays, and only this antibody was evaluated in LSC targeting experiments. To further analyse the safety and efficacy of the molecules and to determine whether the 1 ×- or 2 × SIRPα-αCD123 fusion format would be favourable in future clinical trials, assessing competitive targeting of patient-derived LSCs and healthy haematopoietic stem cells would be very pertinent.

While we are the first to combine CD123 and CD47 targeting, other therapeutic molecules have been developed against CD123 alone [65,66,67]. Talacotuzumab is an αCD123 antibody with a modified Fc region for enhanced ADCC [37, 68]. Unfortunately, talacotuzumab showed limited in vivo efficacy in clinical studies, which has been associated with the compromised NK cell activity in MDS and AML [69,70,71]. This suggests that recruiting other immune cells, such as macrophages, could stimulate a broader response to antibody-based CD123-targeting therapies. The benefit of activating macrophages in AML has been demonstrated by the αCD47 antibody magrolimab in combination with azacytidine [8]. Recent data additionally suggest that upon activation, NK cells can upregulate SIRPα, which leads to strong inhibition of cytotoxicity when interacting with CD47 on the surface of target cells [72]. An effective blockade of CD47 signalling could therefore be the reason we observed an extremely potent upregulation of CD69 on NK cells in response to 2 × SIRPα-αCD123 treatment. This was also indicated by the slight increase in the percentage of CD69+ cells when the αCD47 antibody Hu5F9-G4 was used. A growing body of evidence indicates that adaptive immunity, especially the activation of CD8+ T cells, further contributes to the effects observed in response to CD47-SIRPα inhibition [73,74,75]. As SIRPα-αCD123 fusion antibodies improve phagocytosis of AML patient cells compared to αCD123 while still initiating strong NK cell activation, we propose that SIRPα-αCD123 fusion antibodies stimulate a much broader immune response, including a long-lasting T-cell response.


In summary, we demonstrated that SIRPα-αCD123 antibodies specifically target LSCs, mediate their efficient clearance and stimulate phagocytosis of AML while restricting CD47-related on-target off-leukaemia toxicity. These encouraging results establish SIRPα-αCD123 antibodies as a promising approach for LSC targeting for prolonged remission in AML patients. Future in vivo studies using an appropriate AML mouse model are necessary for the translation of this approach into a clinical setting.

Availability of data and materials

All data generated or analysed during this study are included in this published article [and its supplementary information files].



Acute myeloid leukaemia


Leukemic stem cell


Signal regulatory protein alpha


Fcγ receptor


Myelodysplastic syndrome


Objective response


Complete remission


Natural killer

VL :

Variable light

VH :

And variable heavy


Sodium dodecyl sulphate

EC50 :

Half maximal effective concentration


Polymerase chain reaction

K D :

Equilibrium dissociation constant


Chinese hamster ovary


Peripheral blood mononuclear cells


Patient-derived xenograft


NOD/SCID gamma null mice


Median fluorescence intensity


Red blood cells




Leukaemia-initiating cell


Bioluminescence imaging


Analysis of variance


Antibody-dependent cellular phagocytosis


Antibody-dependent cellular cytotoxicity


Healthy donor


Fluorescence-activated cell sorting


  1. 1.

    Shlush LI, Mitchell A, Heisler L, Abelson S, Ng SWK, Trotman-Grant A, et al. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature. 2017;547(7661):104–8.

    CAS  PubMed  Article  Google Scholar 

  2. 2.

    Wulf GG, Wang RY, Kuehnle I, Weidner D, Marini F, Brenner MK, et al. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood. 2001;98(4):1166–73.

    CAS  PubMed  Article  Google Scholar 

  3. 3.

    Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–47.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  4. 4.

    Tsai RK, Discher DE. Inhibition of “self” engulfment through deactivation of myosin-II at the phagocytic synapse between human cells. J Cell Biol. 2008;180(5):989–1003.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  5. 5.

    Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009;138(2):286–99.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  6. 6.

    Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 2009;138(2):271–85.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  7. 7.

    Vyas P, Knapper S, Kelly R, Salim R, Lubowiecki M, Royston D, et al. Initial phase 1 results of the first-in-class anti-CD47 antibody Hu5F9-G4 in relapsed/refractory acute myeloid leukemia patients. European Hematology Association Annual Meeting, Stockholm. 2018: (Abstract PF232).

  8. 8.

    Chao MP, Takimoto CH, Feng DD, McKenna K, Gip P, Liu J, et al. Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid malignancies. Front Oncol. 2019;9:1380.

    PubMed  Article  Google Scholar 

  9. 9.

    Ring NG, Herndler-Brandstetter D, Weiskopf K, Shan L, Volkmer JP, George BM, et al. Anti-SIRPalpha antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc Natl Acad Sci U S A. 2017;114(49):E10578–85.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  10. 10.

    Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010;142(5):699–713.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  11. 11.

    Weiskopf K, Jahchan NS, Schnorr PJ, Cristea S, Ring AM, Maute RL, et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. J Clin Investig. 2016;126(7):2610–20.

    PubMed  PubMed Central  Article  Google Scholar 

  12. 12.

    Jain S, Van Scoyk A, Morgan EA, Matthews A, Stevenson K, Newton G, et al. Targeted inhibition of CD47-SIRPalpha requires Fc-FcgammaR interactions to maximize activity in T-cell lymphomas. Blood. 2019;134(17):1430–40.

    PubMed  PubMed Central  Article  Google Scholar 

  13. 13.

    Sallman DA, Asch AS, Malki MMA, Lee DJ, Donnellan WB, Marcucci G, et al. The first-in-class anti-CD47 antibody magrolimab (5F9) in combination with azacitidine is effective in MDS and AML patients: ongoing phase 1b results. Blood. 2019;134(Supplement_1):569 (Abstract).

    Article  Google Scholar 

  14. 14.

    Reinhold MI, Lindberg FP, Plas D, Reynolds S, Peters MG, Brown EJ. In vivo expression of alternatively spliced forms of integrin-associated protein (CD47). J Cell Sci. 1995;108:3419–25.

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP. Role of CD47 as a marker of self on red blood cells. Science. 2000;288(5473):2051–4.

    CAS  PubMed  Article  Google Scholar 

  16. 16.

    Piccione EC, Juarez S, Liu J, Tseng S, Ryan CE, Narayanan C, et al. A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells. MAbs. 2015;7(5):946–56.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  17. 17.

    Piccione EC, Juarez S, Tseng S, Liu J, Stafford M, Narayanan C, et al. SIRPalpha-antibody fusion proteins selectively bind and eliminate dual antigen-expressing tumor cells. Clin Cancer Res. 2016;22(20):5109–19.

    CAS  PubMed  Article  Google Scholar 

  18. 18.

    Ponce LP, Fenn NC, Moritz N, Krupka C, Kozik JH, Lauber K, et al. SIRPalpha-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells. Oncotarget. 2017;8(7):11284–301.

    PubMed  PubMed Central  Article  Google Scholar 

  19. 19.

    Jordan CT, Upchurch D, Szilvassy SJ, Guzman ML, Howard DS, Pettigrew AL, et al. The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia. 2000;14(10):1777–84.

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Taussig DC, Pearce DJ, Simpson C, Rohatiner AZ, Lister TA, Kelly G, et al. Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia. Blood. 2005;106(13):4086–92.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  21. 21.

    Haubner S, Perna F, Kohnke T, Schmidt C, Berman S, Augsberger C, et al. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia. 2019;33(1):64–74.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  22. 22.

    Yan B, Chen Q, Shimada K, Tang M, Li H, Gurumurthy A, et al. Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia. Leukemia. 2019;33(4):931–44.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  23. 23.

    Broughton SE, Hercus TR, Nero TL, Dhagat U, Owczarek CM, Hardy MP, et al. Crystallization and preliminary X-ray diffraction analysis of the interleukin-3 alpha receptor bound to the Fab fragment of antibody CSL362. Acta Crystallogr F Struct Biol Commun. 2014;70(Pt 3):358–61.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  24. 24.

    Liu J, Wang L, Zhao F, Tseng S, Narayanan C, Shura L, et al. Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential. PLoS ONE. 2015;10(9):e0137345.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  25. 25.

    Petrova PS, Viller NN, Wong M, Pang X, Lin GH, Dodge K, et al. TTI-621 (SIRPalphaFc): A CD47-blocking innate immune checkpoint inhibitor with broad antitumor activity and minimal erythrocyte binding. Clin Cancer Res. 2017;23(4):1068–79.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  26. 26.

    Hatherley D, Lea SM, Johnson S, Barclay AN. Polymorphisms in the human inhibitory signal-regulatory protein alpha do not affect binding to its ligand CD47. J Biol Chem. 2014;289(14):10024–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  27. 27.

    Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E, et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol. 2010;28(4):570–7.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  28. 28.

    Benthaus T, Schneider F, Mellert G, Zellmeier E, Schneider S, Kakadia PM, et al. Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia. Br J Haematol. 2008;143(2):230–9.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  29. 29.

    Büchner T, Hiddemann W, Wörmann B, Löffler H, Gassmann W, Haferlach T, et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood. 1999;93(12):4116–24.

    PubMed  PubMed Central  Google Scholar 

  30. 30.

    Vinholt PJ, Nybo M, Nielsen CB, Hvas A-M. Light transmission aggregometry using pre-coated microtiter plates and a Victor X5 plate reader. PLoS ONE. 2017;12(10):e0185675.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  31. 31.

    Krupka C, Kufer P, Kischel R, Zugmaier G, Bögeholz J, Köhnke T, et al. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330. Blood. 2014;123(3):356–65.

    CAS  PubMed  Article  Google Scholar 

  32. 32.

    Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, Kohnke T, et al. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. Leukemia. 2016;30(2):484–91.

    CAS  PubMed  Article  Google Scholar 

  33. 33.

    Vick B, Rothenberg M, Sandhofer N, Carlet M, Finkenzeller C, Krupka C, et al. An advanced preclinical mouse model for acute myeloid leukemia using patients’ cells of various genetic subgroups and in vivo bioluminescence imaging. PLoS ONE. 2015;10(3):e0120925.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  34. 34.

    Ebinger S, Zeller C, Carlet M, Senft D, Bagnoli JW, Liu WH, et al. Plasticity in growth behavior of patients’ acute myeloid leukemia stem cells growing in mice. Haematologica. 2020;32:939.

    Google Scholar 

  35. 35.

    Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. J Immunol Methods. 2009;347(1–2):70–8.

    CAS  PubMed  Google Scholar 

  36. 36.

    Kwong LS, Brown MH, Barclay AN, Hatherley D. Signal-regulatory protein alpha from the NOD mouse binds human CD47 with an exceptionally high affinity—implications for engraftment of human cells. Immunology. 2014;143(1):61–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  37. 37.

    Busfield SJ, Biondo M, Wong M, Ramshaw HS, Lee EM, Ghosh S, et al. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia. 2014;28(11):2213–21.

    CAS  PubMed  Article  Google Scholar 

  38. 38.

    Pietsch EC, Dong J, Cardoso R, Zhang X, Chin D, Hawkins R, et al. Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies. Blood Cancer J. 2017;7(2):e536.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  39. 39.

    Ansell SM, Maris M, Lesokhin AM, Chen R, Flinn IW, Sawas A, et al. Phase 1 study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res. 2021;27:2190–9.

    CAS  PubMed  Article  Google Scholar 

  40. 40.

    Bakema JE, van Egmond M. Fc receptor-dependent mechanisms of monoclonal antibody therapy of cancer. Curr Top Microbiol Immunol. 2014;382:373–92.

    CAS  PubMed  Google Scholar 

  41. 41.

    Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994;367(6464):645–8.

    CAS  PubMed  Article  Google Scholar 

  42. 42.

    Sarry JE, Murphy K, Perry R, Sanchez PV, Secreto A, Keefer C, et al. Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rgammac-deficient mice. J Clin Investig. 2011;121(1):384–95.

    CAS  PubMed  Article  Google Scholar 

  43. 43.

    Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci U S A. 2012;109(17):6662–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  44. 44.

    Logtenberg MEW, Scheeren FA, Schumacher TN. The CD47-SIRPalpha immune checkpoint. Immunity. 2020;52(5):742–52.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  45. 45.

    Brooke G, Holbrook JD, Brown MH, Barclay AN. Human lymphocytes interact directly with CD47 through a novel member of the signal regulatory protein (SIRP) family. J Immunol. 2004;173(4):2562–70.

    CAS  PubMed  Article  Google Scholar 

  46. 46.

    Advani R, Bartlett N, Smith S, Roschewski M, Popplewell L, Flinn I, et al. The first in class anti CD47 antibody HU5FY G4 + rituximab induces durable responses in relapsed/refractory dlbcl and indolent lymphoma: interim phase 1B/2 results. Hematol Oncol. 2019;37:89–90.

    Article  Google Scholar 

  47. 47.

    Sallman DA, Asch AS, Kambhampati S, Al Malki MM, Zeidner JF, Donnellan W, Lee DJ, Vyas P, Jeyakumar D, Mannis GN, Tanaka TN, Chai-Ho W, Larson RA, Whiteley AR, Marcucci G, Komrokji RS, Garcia-Manero G, Van Elk J, Lin M, Maute R, Volkmer J-P, Takimoto CH, Chao MP, Daver N. The first-in-class anti-CD47 antibody magrolimab combined with azacitidine is well-tolerated and effective in AML patients: phase 1b results. Blood. 2020;21(Supplement_1):S213.

    Google Scholar 

  48. 48.

    Zeidan AM, DeAngelo DJ, Palmer JM, Seet CS, Tallman MS, Wei X, et al. A phase I study of CC-90002, a monoclonal antibody targeting CD47, in patients with relapsed and/or refractory (R/R) acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS): final results. Blood. 2019;134(1):1320.

    Article  Google Scholar 

  49. 49.

    Qi J, Li J, Jiang B, Jiang B, Liu H, Cao X, et al. A phase I/IIa study of lemzoparlimab, a monoclonal antibody targeting CD47, in patients with relapsed and/or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): initial phase I results. Blood. 2020;136(Supplement 1):30–1.

    Article  Google Scholar 

  50. 50.

    Weiskopf K, Ring AM, Ho CC, Volkmer JP, Levin AM, Volkmer AK, et al. Engineered SIRPalpha variants as immunotherapeutic adjuvants to anticancer antibodies. Science. 2013;341(6141):88–91.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  51. 51.

    Zhao XW, van Beek EM, Schornagel K, Van der Maaden H, Van Houdt M, Otten MA, et al. CD47-signal regulatory protein-alpha (SIRPalpha) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci U S A. 2011;108(45):18342–7.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  52. 52.

    Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N Engl J Med. 2018;379(18):1711–21.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  53. 53.

    Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007;25(11):1315–21.

    CAS  PubMed  Article  Google Scholar 

  54. 54.

    Weinstein JN, van Osdol W. The macroscopic and microscopic pharmacology of monoclonal antibodies. Int J Immunopharmacol. 1992;14(3):457–63.

    CAS  PubMed  Article  Google Scholar 

  55. 55.

    Godwin CD, Gale RP, Walter RB. Gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia. 2017;31(9):1855–68.

    CAS  PubMed  Article  Google Scholar 

  56. 56.

    Fournier E, Duployez N, Ducourneau B, Raffoux E, Turlure P, Caillot D, et al. Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia. Blood. 2020;135(8):542–6.

    PubMed  Article  Google Scholar 

  57. 57.

    Fenwarth L, Fournier E, Cheok M, Boyer T, Gonzales F, Castaigne S, et al. Biomarkers of gemtuzumab ozogamicin response for acute myeloid leukemia treatment. Int J Mol Sci. 2020;21(16):5626.

    CAS  PubMed Central  Article  PubMed  Google Scholar 

  58. 58.

    Boyd-Kirkup J, Thakkar D, Brauer P, Zhou J, Chng W-J, Ingram PJ. HMBD004, a novel anti-CD47xCD33 bispecific antibody displays potent anti-tumor effects in pre-clinical models of AML. Blood. 2017;130(Supplement 1):1378.

    Google Scholar 

  59. 59.

    van der Velden VHJ, te Marvelde JG, Hoogeveen PG, Bernstein ID, Houtsmuller AB, Berger MS, et al. Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood. 2001;97(10):3197–204.

    Article  Google Scholar 

  60. 60.

    van der Jagt RHC, Badger CC, Appelbaum FR, Press OW, Matthews DC, Eary JF, et al. Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model. Can Res. 1992;52(1):89–94.

    Google Scholar 

  61. 61.

    Walter RB, Appelbaum FR, Estey EH, Bernstein ID. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood. 2012;119(26):6198–208.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  62. 62.

    Vergez F, Green AS, Tamburini J, Sarry JE, Gaillard B, Cornillet-Lefebvre P, et al. High levels of CD34+CD38low/-CD123+ blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies Aigues et Maladies du Sang (GOELAMS) study. Haematologica. 2011;96(12):1792–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  63. 63.

    Vergez F, Nicolau-Travers ML, Bertoli S, Rieu JB, Tavitian S, Bories P, et al. CD34(+)CD38(-)CD123(+) leukemic stem cell frequency predicts outcome in older acute myeloid leukemia patients treated by intensive chemotherapy but not hypomethylating agents. Cancers (Basel). 2020;12(5):1174.

    CAS  Article  Google Scholar 

  64. 64.

    Perna F, Berman SH, Soni RK, Mansilla-Soto J, Eyquem J, Hamieh M, et al. Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML. Cancer Cell. 2017;32(4):506-19.e5.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  65. 65.

    Testa U, Pelosi E, Castelli G. CD123 as a therapeutic target in the treatment of hematological malignancies. Cancers (Basel). 2019;11(9):1358.

    CAS  Article  Google Scholar 

  66. 66.

    Jen EY, Gao X, Li L, Zhuang L, Simpson NE, Aryal B, et al. FDA approval summary: tagraxofusp-erzs for treatment of blastic plasmacytoid dendritic cell neoplasm. Clin Cancer Res. 2020;26(3):532–6.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  67. 67.

    Uy GL, Aldoss I, Foster MC, Sayre PH, Wieduwilt MJ, Advani AS, et al. Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia. Blood. 2020;137:751–62.

    Article  CAS  Google Scholar 

  68. 68.

    Smith BD, Roboz GJ, Walter RB, Altman JK, Ferguson A, Curcio TJ, et al. First-in man, phase 1 study of CSL362 (anti-IL3Rα/anti-CD123 monoclonal antibody) in patients with CD123+ acute myeloid leukemia (AML) in CR at high risk for early relapse. Blood. 2014;124(21):120.

    Article  Google Scholar 

  69. 69.

    Epling-Burnette PK, Bai F, Painter JS, Rollison DE, Salih HR, Krusch M, et al. Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood. 2007;109(11):4816–24.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  70. 70.

    Kubasch AS, Schulze F, Giagounidis A, Gotze KS, Kronke J, Sockel K, et al. Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. Leukemia. 2020;34(4):1182–6.

    PubMed  Article  Google Scholar 

  71. 71.

    Montesinos P, Roboz GJ, Bulabois CE, Subklewe M, Platzbecker U, Ofran Y, et al. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. Leukemia. 2020;35:62–74.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  72. 72.

    Deuse T, Hu X, Agbor-Enoh S, Jang MK, Alawi M, Saygi C, et al. The SIRPα–CD47 immune checkpoint in NK cells. J Exp Med. 2021.

    Article  PubMed  PubMed Central  Google Scholar 

  73. 73.

    Tseng D, Volkmer JP, Willingham SB, Contreras-Trujillo H, Fathman JW, Fernhoff NB, et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci U S A. 2013;110(27):11103–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  74. 74.

    Li Y, Zhang M, Wang X, Liu W, Wang H, Yang YG. Vaccination with CD47 deficient tumor cells elicits an antitumor immune response in mice. Nat Commun. 2020;11(1):581.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  75. 75.

    Liu X, Pu Y, Cron K, Deng L, Kline J, Frazier WA, et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med. 2015;21(10):1209–15.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

Download references


The authors are grateful to Bettina Brauchle for help with the AML patient material and to Manuel Albanese, Marcel Stern and Oliver Keppler for help with the leukoreduction chamber material. We thank Maike Fritschle and Fabian Klein for technical assistance in the in vivo experiment, Daniel Bergér for help with the assay setup and Vindi Jurinovic for advice on statistical analysis. We acknowledge the iFlow Core Facility of the university hospital Munich (INST 409/225-1 FUGG) for assistance with the generation of flow cytometry data.


Open Access funding enabled and organized by Projekt DEAL. This study was supported by the Marie-Sklodowska-Curie Training Network “Immutrain” funded by the H2020 Program of the European Union (Grant 641549, KPH), the International Doctoral Program “i-Target” funded by the Elite Network of Bavaria (MS and KPH), the Collaborative Research Center 1243 “Cancer Evolution” of the Deutsche Forschungsgemeinschaft (IJ, MS and KPH), the Deutsche Forschungsgemeinschaft grants HO2489/10-1 and SU197/3-1 (KPH and MS), and the Exist Transfer of Research I grant (NCF).

Author information




BV, BH, SS contributed equally to this work. ST, NCF and KPH designed the experiments and interpreted the data. ST generated and characterized the molecules and performed functional assays with cell lines and patient materials and data analysis. SS contributed to ADCP and SPR analysis and helped with interpreting the data. BV and IJ provided PDX cells, designed the in vivo engraftment assay and performed the experiments after ex vivo ADCC. BV analysed the results of the in vivo engraftment experiment. BH performed experiments with PBMCs and platelets and contributed to autologous ADCP results. AM performed the AML long-term ADCC experiments. EP generated molecules. AR, CA, BT and MS provided AML patient material. AL performed PBMC binding studies. AH provided the leukoreduction chamber material. MS interpreted the data and provided critical feedback and support. ST and NCF wrote the manuscript with input from BV, MS and KPH. KPH supervised the project. All authors approved the final version of the manuscript. All authors read and approved the final manuscript

Corresponding authors

Correspondence to Nadja C. Fenn or Karl-Peter Hopfner.

Ethics declarations

Ethics approval and consent to participate

After obtaining written informed consent in accordance with the Declaration of Helsinki and approval by the Institutional Review Board of the Ludwig-Maximilians-Universität, peripheral blood, bone marrow or leukoreduction material was collected from AML patients and healthy donors. All animal studies were performed in accordance with the current ethical standards of the official committee on animal experimentation (written approval by Regierung von Oberbayern, ROB-55.2Vet-2532. Vet_02-16–7 and ROB-55.2Vet-2532.Vet_03-16–56).

Consent for publication

Not applicable.

Competing interests

KPH, MS and NCF are inventors of a patent application regarding the SIRPα-antibody fusion proteins.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1

. Supplementary tables and figures.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tahk, S., Vick, B., Hiller, B. et al. SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells. J Hematol Oncol 14, 155 (2021).

Download citation


  • CD47
  • Acute myeloid leukaemia
  • CD123
  • Leukemic stem cells
  • Phagocytosis
  • Immunotherapy